QL1706 with chemotherapy and anlotinib for recurrent ovarian cancer

A Single-arm, Multicenter Phase II Clinical Study of QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

This trial will test whether adding QL1706 to chemotherapy and anlotinib helps women with recurrent epithelial ovarian cancer respond better and delay disease progression.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years to 70 Years
• Sex: Female
• Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University (Academic / other)
• Drugs / interventions: bevacizumab, anlotinib, chemotherapy, prednisone, immunotherapy
• Locations: 1 site (Guangzhou, Guangdong)
• Trial ID: NCT07286240 on ClinicalTrials.gov

What this trial studies

This Phase 2 interventional trial combines the investigational agent QL1706 with standard chemotherapy and the anti-angiogenic drug anlotinib in women with recurrent epithelial ovarian cancer. Eligible participants are adult women (18–70 years) with measurable recurrent disease after prior platinum-based therapy, including both platinum-sensitive and platinum-resistant relapses, and ECOG performance status 0–1. The trial will deliver the combination regimen at a single center and monitor tumor response, progression-free survival, and safety outcomes. The approach aims to harness immunomodulation plus anti-angiogenesis alongside cytotoxic therapy to improve control of recurrent disease.

Who should consider this trial

Good fit: Women aged 18–70 with histologically confirmed recurrent epithelial ovarian, fallopian-tube, or primary peritoneal carcinoma who have measurable disease, ECOG 0–1, life expectancy ≥3 months, and prior platinum-based therapy (platinum-sensitive or platinum-resistant) are the intended participants.

Not a fit: Patients with non-epithelial ovarian cancers, poor performance status (ECOG ≥2), no measurable lesions, age outside 18–70, or significant uncontrolled comorbidities are unlikely to benefit from or be eligible for this regimen.

Why it matters

Potential benefit: If successful, the combination could improve tumor response rates and delay progression for women with recurrent ovarian cancer.

How similar studies have performed: Other studies combining immunotherapy with anti-angiogenic agents and chemotherapy have shown promising response signals in ovarian cancer but have not yet produced consistent overall survival benefits.

Eligibility criteria

Inclusion Criteria:

* 1.Capable of understanding and voluntarily signing the written Informed Consent Form (ICF); the ICF must be signed before any study-specific procedures are performed.

  2.Female, aged 18-70 years at the time of ICF signature. 3.Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 4.Life expectancy ≥ 3 months. 5.Histologically confirmed epithelial ovarian cancer (including fallopian-tube and primary peritoneal carcinoma) that has recurred after standard platinum-based therapy:
  1. Platinum-sensitive relapse (recurrence ≥ 6 months after completion of the last platinum-based therapy).
  2. Platinum-resistant relapse (recurrence \< 6 months after completion of the last platinum-based therapy or progression while on PARP-inhibitor maintenance).

     Note: Maintenance PARP inhibitor or bevacizumab after CR/PR to prior chemotherapy, and hormonal therapy, are not counted as additional lines of therapy.

     6.At least one measurable lesion per RECIST v1.1. Lesions previously irradiated or treated with other loco-regional therapy can serve only as non-target lesions unless clear progression is documented or tumor viability is biopsy-proven.

     7.Archived or freshly obtained tumor tissue (primary or relapse) must be available for biomarker analyses. Five unstained formalin-fixed paraffin-embedded (FFPE) slides or a tissue block are required for central PD-L1 testing (slides preferred). If re-biopsy is judged unsafe, the number of slides may be reduced after discussion with the medical monitor.

     8.Adequate organ function at screening:

     Hematology:

     Hb ≥ 90 g/L ANC ≥ 1.5 × 10⁹/L PLT ≥ 100 × 10⁹/L

     Biochemistry:

     Albumin ≥ 29 g/L ALT/AST \< 3 × ULN (\< 5 × ULN if liver metastases) TBIL ≤ 1.5 × ULN Creatinine ≤ 1.5 × ULN 9.Women of child-bearing potential must have a negative serum pregnancy test within 3 days before first dose. If sexually active with a non-sterilized male partner, they must use a highly effective contraceptive method from screening until 6 months after the last study-dose; rhythm or withdrawal methods are not acceptable.

     10.The need for additional cytoreductive surgery is at the investigator's discretion.

     Exclusion Criteria:
* 1.Non-epithelial ovarian malignancies (e.g., carcinosarcoma, sex-cord stromal tumors).

  2.Central-nervous-system metastases or meningeal carcinomatosis. 3.Pleural, pericardial, or ascitic effusions requiring repeat drainage \> once per month.

  4.Active malignancy within 3 years before first dose, except locally curable cancers deemed cured (e.g., squamous- or basal-cell skin cancer, superficial bladder cancer, ductal carcinoma in situ of breast).

  5.Prior systemic anti-cancer therapy within 3 weeks (chemotherapy, bevacizumab/biosimilars, TKI, PARP inhibitor); palliative radiotherapy or immunomodulators (e.g., thymosin, interferon, IL-2) or cancer-treating Chinese patent medicines (e.g., Aidi injection) within 2 weeks; hormonal agents (e.g., tamoxifen, letrozole) within 1 week.

  6.Previous immune-checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.) or agonists of immune co-stimulatory molecules (ICOS, CD40, CD137, GITR, OX40, etc.).

  7.Major surgery, open biopsy, or significant trauma within 4 weeks; elective major surgery planned during study.

  8.Active or likely recurrent autoimmune disease (exceptions: vitiligo, alopecia, psoriasis/eczema not requiring systemic therapy; hypothyroidism from autoimmune thyroiditis on stable replacement; type 1 diabetes on stable insulin).

  9.Systemic corticosteroids \> 10 mg/day prednisone equivalent or other immunosuppressants within 14 days (inhaled, ophthalmic, or topical steroids ≤ 10 mg/day permitted).

  10.Live vaccine within 4 weeks. 11.Primary or secondary immunodeficiency, including positive HIV antibody. 12.Prior solid-organ or allogeneic hematopoietic-stem-cell transplant. 13.History of interstitial lung disease or non-infectious pneumonitis. 14.Severe infection within 4 weeks (complicated infection requiring hospitalization, sepsis, severe pneumonia).

  15.Active infection requiring systemic therapy (including active TB or active syphilis) or systemic antibiotics/antivirals/antifungals within 2 weeks (except suppressive anti-HBV therapy).

  16.Active hepatitis B (HBsAg-positive with HBV DNA \> 1000 IU/mL); active hepatitis C. Inactive HBV carriers with HBV DNA ≤ 1000 IU/mL are eligible. Subjects with cured HCV (HCV Ab-positive and HCV RNA-negative) are eligible.

  17.Inflammatory bowel disease (Crohn's, ulcerative colitis), active diverticulitis, clinical bowel obstruction, or need for parenteral hydration/nutrition or nasogastric tube.

  18.Significant cardiovascular/cerebrovascular disease:
  1. MI, unstable angina, pulmonary embolism, aortic dissection, DVT, arterial thrombo-embolism within 6 months
  2. NYHA class ≥ II heart failure
  3. Serious arrhythmia requiring chronic therapy (stable-rate asymptomatic atrial fibrillation allowed)
  4. CVA within 6 months
  5. LVEF \< 50 %
  6. Prior myocarditis/cardiomyopathy; uncontrolled hypertension (\> 150/100 mmHg) or hypertensive crisis/encephalopathy 19.Peripheral neuropathy ≥ grade 2 (NCI CTCAE v5.0). 20.Unresolved toxicity \> grade 1 from prior anti-cancer therapy (except alopecia).

     21.Severe hypersensitivity to any monoclonal antibody. 22.Pregnancy or lactation. 23.Any condition that, in the investigator's opinion, would compromise safety, interfere with study evaluations, or confound results (e.g., severe concomitant disease or psychiatric disorder).

     24.Known hypersensitivity to any study drug or excipient. 25.Prior gastrointestinal perforation, intra-abdominal abscess, or bowel obstruction within 3 months or radiologic/clinical evidence of obstruction.

     26.Hypertension inadequately controlled on medication (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg).

     27.Coagulopathy (INR \> 2.0 or PT \> 16 s), bleeding diathesis, or thrombolytic/anticoagulant therapy (prophylactic low-dose aspirin or LMWH allowed).

     28.Clinically significant bleeding or bleeding tendency within 3 months (e.g., GI bleeding, hemorrhagic gastritis, vasculitis).

     29.Arterial or venous thrombosis within 6 months (CVA, TIA, intracranial bleed, DVT, PE); superficial vein thrombosis may be allowed at investigator's discretion.

     30.Hereditary or acquired bleeding/thrombotic disorders (e.g., hemophilia, coagulation defects, thrombocytopenia).

     31.Active ulcer, non-healing wound, or fracture. 32.Urine protein ≥ ++ confirmed by 24-h urine protein \> 1.0 g. 33.Prior palliative radiotherapy to \> 5 % of bone-marrow area within 4 weeks. 34.Strong CYP3A4 inducers within 2 weeks or strong CYP3A4 inhibitors within 1 week.

     35.Prior treatment with anlotinib or other small-molecule multi-target TKIs.

Where this trial is running

Guangzhou, Guangdong

• Lipai Chen — Guangzhou, Guangdong, China (Recruiting)

Study contacts

• Study coordinator: chen lipai

Conditions Treatment of Recurrent Ovarian Cancer